PAREXEL International Corporation (NASDAQ:PRXL) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

On August 28, 2017, PAREXEL International Corporation (the “Company”) announced its financial results for the fiscal quarter and year ended June 30, 2017. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

PAREXEL INTERNATIONAL CORP Exhibit
EX-99.1 2 exhibit991_q4fy17.htm EXHIBIT 99.1 Exhibit Exhibit 99.1                        FOR IMMEDIATE RELEASE              PAREXEL INTERNATIONAL REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 RESULTS •Fourth-quarter 2017 service revenue of $557.2 million•Fourth-quarter 2017 GAAP diluted EPS of $0.58; adjusted diluted EPS of $1.02•Full-year 2017 service revenue of $2,…
To view the full exhibit click here

About PAREXEL International Corporation (NASDAQ:PRXL)

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries. Its segments include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI). The CRS segment includes various phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. The PC segment provides technical expertise and advice in areas, such as strategy, drug development, regulatory affairs, strategic compliance and targeted communications services in support of product launch. The Company’s PI segment provides information technology solutions.